$PLSE SEC Filings

Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical data

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

Pulse Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or through Mizuho Securities USA LLC (the “Agent”), as sales agent, shar...

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

Bought 1,024 shares ($50K) · Bought 1,001 shares ($50K)

Bought 1,036 shares ($50K) · Bought 1,034 shares ($50K)

Granted 200,000 Restricted Stock Units · Granted 700,000 Stock Option (right to buy)

No securities owned

Granted 300,000 Stock Option (right to buy)

No securities owned

Granted 44,504 Stock Option (right to buy)

Granted 38,423 Stock Option (right to buy)

Granted 42,495 Stock Option (right to buy)

Granted 30,000 Stock Option (right to buy)